@FiercePharma: ICYMI: Judge halts lawsuit blaming Purdue, Endo and others for epidemic of drug abuse. Article | Follow @FiercePharma
@EricPFierce: Majority of Mylan shareholders approve buyout of Perrigo, despite adamant opposition by its management. Press release | Follow @EricPFierce
@CarlyHFierce: 'No signal' of heart failure risk with Merck's Januvia, analysis confirms. Article | Follow @CarlyHFierce
> Sanofi ($SNY) inked a deal with Google's ($GOOG) newly launched life sciences division to work together on new treatment approaches, including digital-plus-drug approaches. Report
> Eli Lilly & Co. ($LLY) and Boehringer Ingelheim's new diabetes combo med Synjardy--which combines the active ingredient in the SGLT2 drug Jardiance with metformin--won U.S. approval, becoming the third empagliflozin product blessed by the FDA. Release
> Allergan ($AGN) wrapped up its $560-million-plus deal for Naurex and its two antidepressants, which recently posted promising mid-stage data. Release
> Novartis' ($NVS) eye care division Alcon Laboratories, Johnson & Johnson ($JNJ) and Bausch & Lomb struggled to defend their pricing policies in a federal appeals court Thursday, with the judges repeatedly challenging the companies' arguments. Report
Medical Device News
@FierceMedDev: ICYMI Friday: Nerve repair micro-cap AxoGen nabs $17.5M from PE group to get to cash-flow positive. More | Follow @FierceMedDev
@VarunSaxena2: ICYMI: Updated $ABT's interest in $STJ w/ info from old article on their prior partnership. Neat to add context from 2012. Article | Follow @VarunSaxena2
@EmilyWFierce: $GOOG and $SNY are teaming up for #diabetes monitoring. More from the WSJ | Follow @EmilyWFierce
> Google pairs with Sanofi for diabetes monitoring collaboration. Story
> Precedent from Amarin's off-label promotion victory covers devices, too, especially those marketing a surrogate endpoint. Editor's Corner
> Philips debuts two new cardio products to European market at London conference. Article
Biotech News
@FierceBiotech: Alnylam, Medicines Co. say next-gen PCSK9 drug has blockbuster potential. Article | Follow @FierceBiotech
@JohnCFierce: Amicus bags PhIII rare disease drug in $847M Scioderm buyout. News | Follow @JohnCFierce
@DamianFierce: Missed the FDA biosimilar-naming thing because vacation, but I'm a big fan of the phrase "suffix devoid of meaning." More | Follow @DamianFierce
> Intercept wins priority review for OCA. Item
> Sanofi buys into Google's biotech future, pairing up in diabetes. Story
> Bayer takes its heart-failure drug into Phase III after a mid-stage success. Report
> Step 3: After an immunotherapy makeover, CytomX files $100M IPO. More
Animal Health News
> Denver cannabis seller teams with vet to launch pet wellness line. Item
> Cornell U spotlights veterinary profession on Nat Geo reality TV show. News
> Patterson shares fall on missed sales and earnings targets. More
> Young entrepreneur shows off veterinary product at White House Demo Day. Story
> Academic docs and biotechs partner with veterinarians to find cancer cures. Article
Biotech IT News
> Ginkgo Bioworks allies with Ajinomoto to expand into amino acid production. Item
> Venter's HLI nabs Millennium Health COO to oversee global expansion. Report
> Mytrus makes electronic informed consent breakthrough in U.K. Story
> How openFDA's 'crazy collision' of Silicon Valley and federal culture is reshaping the regulator. More
> UCL taps Elsevier resource to advance drug repurposing research. Article
Pharma Marketing News
> The 'Kardashian Effect' on pharma begs the question: Does social media influence drug requests? Story
> The need-to-know from ESC (so far): Merck, BMS, Pfizer and Sanofi. More
> Repatha vs. Praluent matchup has Amgen, Sanofi zeroing in on key details. Article
> Dutch pension fund dumps Mylan on worries about death penalty drug. Item
> Want to improve drug adherence, pharma? Get tracking. More
And Finally... Device maker Medtronic ($MDT) said it had identified genetic abnormalities associated with sudden cardiac death. Report